Emerging Therapies in Metastatic Prostate Cancer-Reference-Cited by-同舟云学术

Emerging Therapies in Metastatic Prostate Cancer

Published:2018-04-11 Issue:6 Volume:20 Page:
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Sonnenburg Daniel W.,Morgans Alicia K.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/article/10.1007/s11912-018-0692-z/fulltext.html

Reference36 articles.

1. Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). . Prostate Cancer SEER Cancer Statistics Review, 1975-2014. 2017.

2. • Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer. N Engl J Med. 2015;373(8):737–46. https://doi.org/10.1056/NEJMoa1503747 . This trial showed that the addition of six cycles of docetaxel to androgen deprivation therapy in newly diagnosed metastatic hormone-sensitive prostate cancer significantly increased overall survival.

3. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial Ann Oncol 2016;27(Supplemental 6).

4. • James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77. https://doi.org/10.1016/S0140-6736(15)01037-5 . This trial showed that the addition of six cycles of docetaxel to androgen deprivation therapy in newly diagnosed metastatic hormone-sensitive prostate cancer significantly increased overall survival.

5. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51. https://doi.org/10.1056/NEJMoa1702900 .

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming chemoresistance and radio resistance in prostate cancer: The emergent role of non-coding RNAs;Pathology - Research and Practice;2024-03

2. Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report;World Journal of Clinical Cases;2023-04-16

3. Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer;Cancers;2023-04-11

4. A Five Glutamine-Associated Signature Predicts Prognosis of Prostate Cancer and Links Glutamine Metabolism with Tumor Microenvironment;Journal of Clinical Medicine;2023-03-14

5. A Novel Four Mitochondrial Respiration-Related Signature for Predicting Biochemical Recurrence of Prostate Cancer;Journal of Clinical Medicine;2023-01-13